A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts
Portfolio Pulse from Benzinga Insights
Halozyme Therapeutics (NASDAQ:HALO) has received mixed analyst ratings, with a majority being bullish. The average 12-month price target is $61.42, reflecting a 2.79% increase from the previous target. The company shows strong financial metrics but has a high debt-to-equity ratio.
October 04, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has received a mix of bullish and somewhat bullish ratings from analysts, with an average price target increase to $61.42. The company's financials are strong, but it has a high debt-to-equity ratio.
The majority of analysts are bullish on HALO, with a significant increase in the average price target, indicating positive sentiment. The company's strong financial metrics, such as high net margin and ROE, support this outlook. However, the high debt-to-equity ratio poses a risk, which tempers the overall positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100